Stephen Z Levine1, Arad Kodesh1,2, Alexander Viktorin3,4,5, Lauren Smith4, Rudolf Uher5,6, Abraham Reichenberg3, Sven Sandin3,4. 1. Department of Community Mental Health, University of Haifa, Haifa, Israel. 2. Department of Mental Health, Meuhedet Health Services, Tel Aviv, Israel. 3. The Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 6. Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
Importance: The association of maternal use of folic acid and multivitamin supplements before and during pregnancy with the risk of autism spectrum disorder (ASD) in offspring is unclear. Objective: To examine the associations between the use of maternal folic acid and multivitamin supplements before and during pregnancy and the risk of ASD in offspring. Design, Setting, and Participants: A case-control cohort study of 45 300 Israeli children born between January 1, 2003, and December 31, 2007, were followed up from birth to January 26, 2015, for the risk of ASD. The cases were all children diagnosed with ASD and the controls were a random sample of 33% of all live-born children. Exposures: Maternal vitamin supplements were classified for folic acid (vitamin B9), multivitamin supplements (Anatomical Therapeutic Chemical A11 codes vitamins A, B, C, and D), and any combination thereof exposed in the intervals before and during pregnancy. Main Outcomes and Measures: The association between maternal vitamin supplementation and the risk of ASD in offspring was quantified with relative risks (RRs) and their 95% CIs fitting Cox proportional hazards regression models adjusted for confounders. Sensitivity analyses were performed to test the robustness of the results. Results: Of the 45 300 children in the study (22 090 girls and 23 210 boys; mean [SD] age, 10.0 [1.4] years at the end of follow-up), 572 (1.3%) received a diagnosis of ASD. Maternal exposure to folic acid and/or multivitamin supplements before pregnancy was statistically significantly associated with a lower likelihood of ASD in the offspring compared with no exposure before pregnancy (RR, 0.39; 95% CI, 0.30-0.50; P < .001). Maternal exposure to folic acid and/or multivitamin supplements during pregnancy was statistically significantly associated with a lower likelihood of ASD in offspring compared with no exposure during pregnancy (RR, 0.27; 95% CI, 0.22-0.33; P < .001). Corresponding RRs were estimated for maternal exposure to folic acid before pregnancy (RR, 0.56; 95% CI, 0.42-0.74; P = .001), maternal exposure to folic acid during pregnancy (RR, 0.32; 95% CI, 0.26-0.41; P < .001), maternal exposure to multivitamin supplements before pregnancy (RR, 0.36; 95% CI, 0.24-0.52; P < .001), and maternal exposure to multivitamin supplements during pregnancy (RR, 0.35; 95% CI, 0.28-0.44; P < .001). The results generally remained statistically significant across sensitivity analyses. Conclusions and Relevance: Maternal exposure to folic acid and multivitamin supplements before and during pregnancy is associated with a reduced risk of ASD in the offspring compared with the offspring of mothers without such exposure.
Importance: The association of maternal use of folic acid and multivitamin supplements before and during pregnancy with the risk of autism spectrum disorder (ASD) in offspring is unclear. Objective: To examine the associations between the use of maternal folic acid and multivitamin supplements before and during pregnancy and the risk of ASD in offspring. Design, Setting, and Participants: A case-control cohort study of 45 300 Israeli children born between January 1, 2003, and December 31, 2007, were followed up from birth to January 26, 2015, for the risk of ASD. The cases were all children diagnosed with ASD and the controls were a random sample of 33% of all live-born children. Exposures: Maternal vitamin supplements were classified for folic acid (vitamin B9), multivitamin supplements (Anatomical Therapeutic Chemical A11 codes vitamins A, B, C, and D), and any combination thereof exposed in the intervals before and during pregnancy. Main Outcomes and Measures: The association between maternal vitamin supplementation and the risk of ASD in offspring was quantified with relative risks (RRs) and their 95% CIs fitting Cox proportional hazards regression models adjusted for confounders. Sensitivity analyses were performed to test the robustness of the results. Results: Of the 45 300 children in the study (22 090 girls and 23 210 boys; mean [SD] age, 10.0 [1.4] years at the end of follow-up), 572 (1.3%) received a diagnosis of ASD. Maternal exposure to folic acid and/or multivitamin supplements before pregnancy was statistically significantly associated with a lower likelihood of ASD in the offspring compared with no exposure before pregnancy (RR, 0.39; 95% CI, 0.30-0.50; P < .001). Maternal exposure to folic acid and/or multivitamin supplements during pregnancy was statistically significantly associated with a lower likelihood of ASD in offspring compared with no exposure during pregnancy (RR, 0.27; 95% CI, 0.22-0.33; P < .001). Corresponding RRs were estimated for maternal exposure to folic acid before pregnancy (RR, 0.56; 95% CI, 0.42-0.74; P = .001), maternal exposure to folic acid during pregnancy (RR, 0.32; 95% CI, 0.26-0.41; P < .001), maternal exposure to multivitamin supplements before pregnancy (RR, 0.36; 95% CI, 0.24-0.52; P < .001), and maternal exposure to multivitamin supplements during pregnancy (RR, 0.35; 95% CI, 0.28-0.44; P < .001). The results generally remained statistically significant across sensitivity analyses. Conclusions and Relevance: Maternal exposure to folic acid and multivitamin supplements before and during pregnancy is associated with a reduced risk of ASD in the offspring compared with the offspring of mothers without such exposure.
Authors: Philippe De Wals; Fassiatou Tairou; Margot I Van Allen; Soo-Hong Uh; R Brian Lowry; Barbara Sibbald; Jane A Evans; Michiel C Van den Hof; Pamela Zimmer; Marian Crowley; Bridget Fernandez; Nora S Lee; Theophile Niyonsenga Journal: N Engl J Med Date: 2007-07-12 Impact factor: 91.245
Authors: Olga Egorova; Robin Myte; Jörn Schneede; Bruno Hägglöf; Sven Bölte; Erik Domellöf; Barbro Ivars A'roch; Fredrik Elgh; Per Magne Ueland; Sven-Arne Silfverdal Journal: Mol Autism Date: 2020-01-16 Impact factor: 7.509
Authors: Derrick Ssewanyana; Julia A Knight; Stephen G Matthews; Jody Wong; Nadya Adel Khani; Jennifer Lye; Kellie E Murphy; Kim Foshay; Justin Okeke; Stephen J Lye; Rayjean J Hung Journal: Pediatr Res Date: 2022-03-14 Impact factor: 3.756
Authors: Magdalena Janecka; Arad Kodesh; Stephen Z Levine; Shari I Lusskin; Alexander Viktorin; Rayees Rahman; Joseph D Buxbaum; Avner Schlessinger; Sven Sandin; Abraham Reichenberg Journal: JAMA Psychiatry Date: 2018-12-01 Impact factor: 21.596
Authors: Ramkripa Raghavan; Jacob Selhub; Ligi Paul; Yuelong Ji; Guoying Wang; Xiumei Hong; Barry Zuckerman; M Daniele Fallin; Xiaobin Wang Journal: Am J Clin Nutr Date: 2020-11-11 Impact factor: 7.045
Authors: Jacqueline M Barkoski; Claire Philippat; Daniel Tancredi; Rebecca J Schmidt; Sally Ozonoff; Dana Boyd Barr; William Elms; Deborah H Bennett; Irva Hertz-Picciotto Journal: Environ Res Date: 2020-11-18 Impact factor: 6.498
Authors: Katharine K Brieger; Kelly M Bakulski; Celeste L Pearce; Ana Baylin; John F Dou; Jason I Feinberg; Lisa A Croen; Irva Hertz-Picciotto; Craig J Newschaffer; M Daniele Fallin; Rebecca J Schmidt Journal: J Autism Dev Disord Date: 2021-06-10